Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5779430

CCOc1ccccc1CN1CCC2(CC1)CCN(C(=O)c1ccc(CC=O)cc1)CC2.O=C(O)C(F)(F)F

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 7/20 0.57
USP2 O75604 4/20 0.57
CHRM2 P08172 2/20 0.55
CHRM3 P20309 2/20 0.55
CCR8 P51685 8/20 0.55
KCNH2 Q12809 8/20 0.55
TSHR P16473 4/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CYP3A4 P08684 2/20 0.55
ALDH1A1 P00352 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401889 0.95 CYP2D6 (0.63) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5431198 0.92 CYP2D6 (0.60) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5431336 0.91 CCR8 (0.62) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5436926 0.90 CYP2D6 (0.58) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5433691 0.90 CYP2D6 (0.62) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5431280 0.89 CYP2D6 (0.61) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5437756 0.89 CYP2D6 (0.61) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5432464 0.88 CCR8 (0.70) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5437437 0.88 USP2 (0.65) CYP2D6USP2CHRM2CHRM3CCR8
Trifluoroacetic Acid SCHEMBL5431551 0.88 TSHR (0.59) CYP2D6USP2CHRM2CHRM3CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP disclosed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO disclosed